title: Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
abstract: Bronchioalveolar carcinoma of the lung represents increasingly recognized clinical entity with relatively high probability of response to epidermal growth factor receptor tyrosine kinase inhibitors. Patients who respond to these agents eventually develop resistance. In this case report, we describe a patient who relapsed after gefitinib treatment and achieved unusual response to vinflunine single-agent chemotherapy, despite earlier progression to a combination of another vinca alkaloid and cisplatin. Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed.
authors.affiliation: Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA. Rafal.Dziadziuszko@UCHSC.edu
authors.forename: Rafal
authors.initials: R
authors.lastname: Dziadziuszko
authors.forename: Anna
authors.initials: A
authors.lastname: Siemiatkowska
authors.forename: Janusz
authors.initials: J
authors.lastname: Limon
authors.forename: Witold
authors.initials: W
authors.lastname: Rzyman
authors.forename: Jacek
authors.initials: J
authors.lastname: Jassem
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
authors.forename: Marileila
authors.initials: M
authors.lastname: Varella-Garcia
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib